Author: Balkhair, A; Al-Zakwani, I.; Al Busaidi, M.; Al-Khirbash, A.; Al Mubaihsi, S.; BaTaher, H.; Al Aghbari, J.; Al Busaidi, I.; Al Kindi, M.; Baawain, S.; Al Alawi, A.; Al Lawati, A.; Al Rawahi, B.; Al-Baimani, K.; Al Zidi, K.; Elfatih, N.; Dawud, B.; John, B.; Rehman, F.; Yousif, F.; Al Khadouri, G.; Saber, I.; Lal, J.; Gargouri, M.; Al-Ward, M.; AbuDraz, N.; Al Ruqeishi, S.; Kumar, S.; Abdelmottaleb, W.; Al-Naamani, Z.; Bin Nazar, Z.; Balkhair, O.
Title: Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: results of a prospective, open-label, interventional study Cord-id: bz71tdh4 Document date: 2020_11_17
ID: bz71tdh4
Snippet: OBJECTIVE: To evaluate the efficacy of anakinra in patients who were admitted to hospital for severe COVID-19 pneumonia requiring high oxygen therapy. METHODS: A prospective, open-label, interventional study in adults hospitalized with severe COVID-19 pneumonia was conducted. Patients in the interventional arm received subcutaneous anakinra (100 mg twice daily for 3 days, followed by 100 mg daily for 7 days) in addition to standard treatment. Main outcomes were need for mechanical ventilation an
Document: OBJECTIVE: To evaluate the efficacy of anakinra in patients who were admitted to hospital for severe COVID-19 pneumonia requiring high oxygen therapy. METHODS: A prospective, open-label, interventional study in adults hospitalized with severe COVID-19 pneumonia was conducted. Patients in the interventional arm received subcutaneous anakinra (100 mg twice daily for 3 days, followed by 100 mg daily for 7 days) in addition to standard treatment. Main outcomes were need for mechanical ventilation and in-hospital death. Secondary outcomes included successful weaning from supplemental oxygen and change in inflammatory biomarkers. Outcomes were compared with those of historical controls who received standard treatment and supportive care. RESULTS: A total of 69 patients were included; 45 anakinra-treated and 24 historical controls. Need for mechanical ventilation occurred in 14 (31%) in the anakinra-treated group and 18 (75%) in the historical cohort (p < 0.001). In-hospital death occurred in 13 (29%) in the anakinra-treated group and 11 (46%) in the historical cohort (p = 0.082). Successful weaning from supplemental oxygen to ambient air was attained in 25 (63%) in the anakinra-treated compared with 6 (27%) in the historical cohort (p = 0.008). Patients who received anakinra showed significant reduction in inflammatory biomarkers. CONCLUSION: In patients with severe COVID-19 pneumonia and high oxygen requirement, anakinra could represent an effective treatment option and may confer clinical benefit. TRIAL REGISTRATION NUMBER: ISRCTN74727214.
Search related documents:
Co phrase search for related documents- abdominal surgery and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- absolute lymphocyte count and active cancer: 1, 2
- absolute lymphocyte count and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- absolute neutrophil and active cancer: 1, 2, 3
- absolute neutrophil and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- absolute neutrophil count and active cancer: 1, 2, 3
- absolute neutrophil count and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- absolute platelet count neutrophil count and active cancer: 1
- absolute platelet count neutrophil count and logistic regression: 1, 2, 3
- active cancer and liver enzyme: 1
- active cancer and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- acute lung injury and logistic regression: 1, 2, 3, 4
- liver aminotransferase and logistic regression: 1, 2, 3, 4, 5
- liver enzyme and logistic regression: 1
- logistic regression and long duration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
Co phrase search for related documents, hyperlinks ordered by date